, Tracking Stock Market Picks
Enter Symbol:
Ym Biosciences, Inc. (YMI) [hlAlert]

up 113.04 %

Ym Biosciences, Inc. (YMI) rated Buy by Merriman

Posted on: Thursday,  Nov 5, 2009  8:25 AM ET by Merriman

Merriman rated Buy Ym Biosciences, Inc. (AMEX: YMI) on 11/05/2009, when the stock price was $1.38. Since
then, Ym Biosciences, Inc. has gained 113.04% as of 02/08/2013's recent price of $2.94.
If you would have followed this Merriman's recommendation on YMI, you would have gained 113.04% of your investment in 1191 days.

YM BioSciences Inc. is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. The Company owns or in-license substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. The Company?s portfolio of products in active clinical development includes one anti-cancer agent (a monoclonal antibody) in a number of clinical trials targeting more than 10 different tumors and/or stages of cancer, and an inhalation-delivery approach for fentanyl to treat acute pain, including cancer pain. The Company?s two product candidates in the clinical stage of development, as of June 30, 2009, were NIMOTUZUMAB and AeroLEF. Its three additional products licensed that are not in clinical development include Tesmilifene and two anti-cancer vaccines, a TGFα vaccine and a HER1-targeting vaccine.

Merriman provides advanced tools for acquiring such information. These tools integrate a combination of cycles, geocosmic signatures and trend analysis patterns in assisting the serious investor in their interpretation of the various financial markets and the general economy. In today's fast paced and seemingly chaotic marketplace, you need the edge that only a broader analysis of human activity can provide.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/5/2009 8:25 AM Buy
as of 12/31/2009
1 Week up  65.89 %
1 Month up  81.35 %
3 Months up  55.07 %
1 YTD up  55.07 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy